R. Costa

发表

Glucose metabolism in the idiopathic blepharoptosis: Utility of the Oral Glucose Tolerance Test (OGTT) and of the Insulin Resistance Index

D. Consoli, A. Siniscalchi, D. Branca, 2009, Journal of the Neurological Sciences.

Incidence of treatment-emergent adverse events in Parkinson's disease patients according to baseline mao-b inhibitors use: Post-hoc analysis from double-blind combined BIPARK-I and II data

E. Tolosa, W. Poewe, A. Lees, 2019, Journal of the Neurological Sciences.

Incidence of treatment-emergent adverse events in Parkinson's Disease patients according to baseline body mass index: Post-hoc analysis from double-blind combined BIPARK-I and II data

E. Tolosa, W. Poewe, A. Lees, 2019, Journal of the Neurological Sciences.

Incidence of treatment-emergent adverse events in Parkinson's disease patients according to baseline dopamine agonist use: Post-hoc analysis from double-blind combined BIPARK-I and II data

O. Rascol, A. Lees, J. Ferreira, 2019, Journal of the Neurological Sciences.

Incidence of treatment-emergent adverse events in Parkinson's disease patients according to baseline disease severity: Post-hoc analysis from double-blind combined BIPARK-I and II data

O. Rascol, A. Lees, J. Ferreira, 2019, Journal of the Neurological Sciences.

Efficacy of opicapone in Parkinson’s disease patients according to baseline presence of dyskinesia: A post-hoc analysis from combined BIPARK-I and II

H. Reichmann, A. Lees, J. Ferreira, 2019, Journal of the Neurological Sciences.

Incidence of treatment-emergent adverse events in Parkinson's disease patients according to race: Post-hoc analysis from double-blind combined BIPARK-I and II data

O. Rascol, A. Lees, J. Ferreira, 2019, Journal of Neurological Sciences.

Incidence of treatment-emergent adverse events in Parkinson's disease patients according to gender: Post-hoc analysis from double-blind combined BIPARK-I and II data

E. Tolosa, W. Poewe, A. Lees, 2019, Journal of the Neurological Sciences.

Efficacy and safety of opicapone, a new COMT-inhibitor, for the treatment of motor fluctuations in Parkinson's Disease patients: BIPARK-II study

A. Lees, J. Ferreira, P. Soares-da-Silva, 2013, Journal of the Neurological Sciences.

127EFFICACY AND SAFETY OF OPICAPONE IN PATIENTS OVER 70 YEARS WITH PARKINSON’S DISEASE AND MOTOR FLUCTUATIONS

A. Lees, J. Ferreira, R. Costa, 2019, Age and Ageing.